Drug Database
BE

bevacizumab (BP 01 / Bevqolva / BP01)

✓ Approved

Aurobindo Pharma Limited · VEGFA · Monoclonal Antibodies

What is bevacizumab?

bevacizumab is a monoclonal antibodies developed by Aurobindo Pharma Limited. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesBP 01, Bevqolva, BP01
CompanyAurobindo Pharma Limited
Drug ClassMonoclonal Antibodies, Antibody
Molecular TargetVEGFA
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Aurobindo Pharma Limited

Mechanism of Action

Molecular Targets

bevacizumab acts on 1 molecular target:

VEGFAvascular endothelial growth factor A (VPF, MVCD1)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

bevacizumab is developed for 9 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer stage IV✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer metastatic✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Ovarian cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Renal cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Colorectal cancer✓ Approved

+4 more indications available with a free account

Sign up free to view all indications →

Related Research Articles

PubMedMedicine2026-07-25

Efficacy and prognostic factors of first-line bevacizumab plus chemotherapy in elderly patients with advanced driver gene-negative lung adenocarcinoma: A retrospective study.

Li Shuiyao S, Wang Shaojun S, Cao Ranhua R

We aimed to evaluate clinical outcomes and identify prognostic indicators in elderly patients with driver gene-negative advanced lung adenocarcinoma treated with first-line bevacizumab-based therapy. Elderly patients (≥65 years) with driver gene-negative advanced lung adenocarcinoma treated between January 2020 and December 2024 were retrospectively included. According to first-line treatment strategies, patients were divided into a chemotherapy-alone group and a bevacizumab plus chemotherapy group. Progression-free survival (PFS) and overall survival (OS) were analyzed using univariate and multivariate Cox regression models. A total of 169 patients were included. In the bevacizumab group, the median OS was 47 months and the median PFS was 24 months. Multivariate analysis showed that prognostic nutritional index (PNI), vascular endothelial growth factor A, carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA-125), and bevacizumab treatment were independent prognostic factors for PFS. Additionally, neutrophil-to-white blood cell ratio (NWR), neutrophil-to-lymphocyte ratio, PNI, vascular endothelial growth factor A, CA-125, and bevacizumab treatment were independently associated with OS. Our findings suggest that bevacizumab combined with chemotherapy is associated with favorable survival outcomes in elderly patients with driver gene-negative advanced lung adenocarcinoma. Inflammation-, nutrition-, and tumor burden-related biomarkers may help predict survival and assist in risk stratification.

PMID 42499069
Read full article →
PubMedInternational journal of pharmaceutics2026-07-25

AI-enabled lyophilization of advanced biologics: process intelligence, quality assessment, and formulation opportunities.

Liu Xiangjian X, Caprio Giuseppe Di GD, Du Yanan Y

Lyophilization is a key stabilization strategy for advanced biologics, including protein therapeutics, nucleic-acid-based products, extracellular vesicles, and other highly labile biopharmaceutical systems. However, the development of lyophilized biologic products remains constrained by the intrinsic complexity of coupled heat and mass transfer, limited real-time process observability, formulation-dependent instability, and the difficulty of linking process parameters to product-relevant critical quality attributes. In this context, artificial intelligence (AI) is emerging not merely as an auxiliary optimization tool, but as an enabling approach for data-driven process understanding, predictive quality assessment, and rational formulation-process development. This review focuses on recent progress and emerging opportunities at the intersection of AI-enabled lyophilization and advanced biologic preservation, with particular emphasis on process intelligence and formulation intelligence. We discuss how machine learning, computer vision, spectroscopy-integrated analytics, hybrid modeling, and digital twins are being explored to improve process modeling, state estimation, cycle optimization, defect detection, and critical quality attribute prediction, while highlighting formulation design as a strategically important but still early-stage frontier. We further propose that future progress in lyophilization of advanced biologics will increasingly rely on integrated frameworks that connect mechanistic knowledge, multimodal characterization, AI-assisted decision support, and product-relevant validation across both process development and formulation design.

PMID 42497936
Read full article →
PubMedWorld journal of otorhinolaryngology - head and neck surgery2026-07-25

A Delphi Consensus on Clinical Features, Diagnosis, and Treatment of Chronic Rhinosinusitis With Nasal Polyps in the ASEAN Region.

Abdullah Baharudin B, Govindaraju Revadi R, Husain Salina S, Siow Jin Keat JK et al.

Chronic rhinosinusitis with nasal polyps (CRSwNP) impacts patients' concentration, ability to work, and overall quality of life. Current treatment options include topical and oral medications, and surgery. Recent evidence supports the efficacy of biologics in improving symptoms and quality of life. This study addresses the lack of consensus in the ASEAN region, providing guidance for otolaryngologists on appropriate CRSwNP management. A modified Delphi panel was conducted to gather expert opinion and establish consensus on the use of biologics and management of CRSwNP among otolaryngologists in the ASEAN region. Statements were developed based on a literature review and inputs from a Steering Committee of eight experts from Malaysia, Singapore, and Thailand. A three-stage process was utilized for consensus generation: two online surveys for voting by at least 12 panelists from seven ASEAN countries, followed by moderated online Consensus Meetings with the Steering Committee. Consensus was achieved on 61/69 statements (88%). In Rounds 1 and 2, 37/67 statements (55%) and 13/28 statements (46%) achieved consensus, respectively. During the moderated Consensus Meetings, consensus was achieved on 12/16 statements (75%). Key aspects addressed include symptoms, comorbidities, diagnosis, and treatment pathways, with a focus on biologics. Eligibility criteria and considerations for biologic use were also defined. Insights from this Delphi consensus provide guidance on biologic use for managing CRSwNP in the ASEAN region. Future efforts, such as developing a regional guideline, continued medical education, and further research are essential for appropriate biologic use.

PMID 42500090
Read full article →
PubMedRespiratory medicine2026-07-25

Step-DAWN: an Italian algorithm proposed for the management of inhaled corticosteroids in severe asthma.

Pini Laura L, Beghe' Bianca B, Bonini Matteo M, Caminati Marco M et al.

Biologics have transformed the management of severe asthma, establishing clinical remission as a realistic treatment objective. Moreover, they offer the potential to reduce background treatment with inhaled corticosteroids (ICS). Although guidelines recommend ICS dose reduction in patients achieving disease control, they provide limited guidance on how to implement tapering. In this context, we developed Step-DAWN (De-escalation of ICS in Asthma With a Novel algorithm), a consensus-based protocol that guides ICS tapering in adults with severe asthma receiving biologic therapy. Step-DAWN was ideated through a modified Delphi process; a Steering Committee consisting of two Italian specialists and two pharmaceutical Medical Affairs professionals drafted 30 statements, which were voted by an Expert Panel comprising 12 specialists. Consensus was reached on 21 of 30 statements in the first round; three other statements reached consensus in the second round; six statements did not reach consensus. The Step-DAWN protocol was designed based on 24 statements that achieved consensus. Patients eligible to Step-DAWN should have maintained the four criteria of complete clinical remission (cCR) for at least 6 months. ICS dose should be reduced gradually, with follow-up assessments not exceeding 6 months. In case of loss of eligibility criteria, potential causes should be addressed before reattempting tapering. Fractional exhaled nitric oxide (FeNO) and blood eosinophil count (BEC) were identified as key biomarkers for monitoring airway inflammation. Step-DAWN is the first consensus-based protocol designed by Italian specialists to provide guidance for ICS tapering in patients with severe asthma treated with biologics.

PMID 42498253
Read full article →
PubMedJPGN reports2026-07-25

Successful treatment of eosinophilic esophagitis with upadacitinib prescribed for atopic dermatitis.

Nguyen Nathalie N, Bauer Maureen M

We describe a pediatric patient treated with upadacitinib for atopic dermatitis (AD) who subsequently achieved sustained clinical and histologic remission of eosinophilic esophagitis (EoE). Upadacitinib is an oral small molecule selective Janus kinase 1 inhibitor that inhibits janus kinase-signal transduction and activation of transcription (JAK-STAT) pathway with wide inhibitory effects on the immune system, including Th2 signaling pathways. Therefore, it leads to broad suppression of inflammatory cytokines, including interleukin-4 (IL-4), interleukin-13 (IL-13), and thymic stromal lymphopoietin (TSLP), that play a central role in the pathogenesis of EoE. Given the broad signaling pathway, if a patient is started on upadacitinib for other indications, cessation of other therapies, particularly biologics like dupilumab, should be considered on a case-by-case basis.

PMID 42499727
Read full article →
PubMedGynecologic oncology reports2026-07-25

Durable response to pembrolizumab plus axitinib in platinum-resistant ovarian clear cell carcinoma: A case report.

Patel Nikhil S NS, Cook Joshua J JJ, Valcana Danielle E DE, Poiesz Michael J MJ et al.

Ovarian clear cell carcinoma (OCCC) is a rare and aggressive histologic subtype of epithelial ovarian cancer characterized by intrinsic chemoresistance and limited treatment options in the platinum-resistant setting. Immune checkpoint inhibitors and VEGFR-targeted therapies have demonstrated synergistic activity across multiple malignancies, though their role in OCCC remains incompletely defined. Axitinib is a selective VEGFR1-3 tyrosine kinase inhibitor approved for renal cell carcinoma but not OCCC. We report a 39-year-old female with FIGO stage IVA platinum-resistant OCCC who achieved durable disease control with pembrolizumab plus axitinib, despite prior mixed response to first-line therapies including bevacizumab. Tumor profiling demonstrated microsatellite stability, low tumor mutational burden, PD-L1 expression (TPS 5%), ARID1A mutation, and TP53 alteration. Serial imaging demonstrated sustained radiographic improvement followed by imaging findings suspicious for disease progression after approximately 23 months of disease control. This case highlights the potential therapeutic relevance of VEGFR inhibition combined with immune checkpoint blockade in platinum-resistant OCCC. In a setting with limited effective options, this combination strategy may provide meaningful clinical benefit in selected patients.

PMID 42500113
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about bevacizumab